We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Avalon Pharmaceuticals Announces Small Molecule Drug Discovery Program
News

Avalon Pharmaceuticals Announces Small Molecule Drug Discovery Program

Avalon Pharmaceuticals Announces Small Molecule Drug Discovery Program
News

Avalon Pharmaceuticals Announces Small Molecule Drug Discovery Program

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Avalon Pharmaceuticals Announces Small Molecule Drug Discovery Program "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Avalon Pharmaceuticals, Inc. has announced that it is entering into collaboration with Novartis to discover small molecule therapeutic compounds targeted against a pathway selected by Novartis.

Avalon will use its AvalonRx® drug discovery engine in this pilot study to identify hits from compounds in Novartis' chemical library.

Novartis will be responsible for lead optimization, preclinical and clinical testing of any resulting product candidates, as well as all future development and sales and marketing activities.

Under the terms of the agreement, Avalon will receive an upfront payment, research support, and milestone payments.

"We are very pleased to enter this drug discovery collaboration with one of the top pharmaceutical companies in the world," stated Ken Carter, Ph.D., CEO of Avalon.

"As our second chemical genomics deal since June, this collaboration is further validation of the potential value of our AvalonRx® drug discovery engine."

Advertisement